Effects of Erythropoietin on Tumor Growth and Angiogenesis
Author Information
Author(s): Hardee M E, Kirkpatrick J P, Shan S, Snyder S A, Vujaskovic Z, Rabbani Z N, Dewhirst M W, Blackwell K L
Primary Institution: Duke University Medical Center
Hypothesis
Does recombinant erythropoietin (rEpo) affect tumor growth and angiogenesis in rodent and human tumor models?
Conclusion
The study found that rEpo does not promote tumor growth or angiogenesis in the tested models.
Supporting Evidence
- All four tumor cell lines used in this experiment expressed Epo receptor.
- Treatment with Epo produced a significant increase in hematocrit compared to the control group.
- There was no statistical difference in tumor growth or proliferation rate between Epo-treated and control groups.
- Epo did not stimulate tumor angiogenesis at any time point.
Takeaway
This study shows that a drug called erythropoietin, which is supposed to help with oxygen in tumors, doesn't actually make the tumors grow or get more blood vessels.
Methodology
The study used various rodent and human tumor models to assess the effects of rEpo on tumor growth and angiogenesis through measurements of tumor volume and vascular length density.
Potential Biases
Potential bias due to the use of specific tumor lines and the controlled environment of the study.
Limitations
The study was limited to specific tumor models and may not generalize to all types of tumors.
Participant Demographics
Female BALB/C mice and Fischer 344 rats were used in the experiments.
Statistical Information
P-Value
3.2 × 10−8
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website